ERBB2 and breast carcinoma: First, there have been five failed phase III adjuvant trials with VEGFpathway inhibitors, including four with the VEGF neutralizing antibody bevacizumab (in combinationwith chemotherapy or an anti-HER2 antibody) in colorectal carcinoma (CRC) (AVANT and C-08) (deGramont et al, 2012) andtriple-negative and HER2+ breast carcinoma (BEATRICE and BETH, respectively)(Cameron et al, 2013), and one withthe VEGF receptor tyrosine kinase inhibitor (RTKI) sorafenib in hepatocellular carcinoma (HCC)(Bruix et al, 2014).